Marine n-3 Polyunsaturated Fatty Acids in Patients With End-stage Renal Failure and in Subjects Without Kidney Disease: A Comparative Study

Madsen, Trine; Christensen, Jeppe H.; Svensson, My; Witt, Petra Mariann; Toft, Egon; Schmidt, Erik Berg

doi:10.1053/j.jrn.2010.06.020

Cited by 42 publications

(27 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma 17-HDHA was 1e2 fold higher in the n-3 fatty acid group and was significantly related to the increase in platelet DHA after n-3 fatty acid supplementation. Patients with CKD have reduced levels of plasma n-3 fatty acids compared with healthy individuals [20], and thus a reduced capacity to synthesize SPMs under basal conditions. Therefore, the finding that supplementing CKD patients with n-3 fatty acids can reverse these deficiencies is clinically significant.…”

Section: Discussionmentioning

confidence: 99%

A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…It should, however, be appreciated that the fish score gives a rather crude measure of consumption and particularly of intake of EPA and DHA, which is a limitation to the study. Previous studies have described that US hemodialysis (HD) patients have much lower fish intake than recommended [32] as well as lower levels of n -3 PUFA compared with controls [33]. In contrast, HD patients in South Korea [34] and peritoneal dialysis patients in Greece [35] had similar levels of n -3 PUFA compared with the background population.…”

Section: Discussionmentioning

confidence: 99%

Long chain n-3 polyunsaturated fatty acids and vascular function in patients with chronic kidney disease and healthy subjects: a cross-sectional and comparative study

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundPatients with chronic kidney disease have a markedly increased cardiovascular mortality compared with the general population. Long chain n-3 polyunsaturated fatty acids have been suggested to possess cardioprotective properties. This cross-sectional and comparative study evaluated correlations between hemodynamic measurements, resistance artery function and fish consumption to the content of long chain n-3 polyunsaturated fatty acids in adipose tissue, a long-term marker of seafood intake.MethodsSeventeen patients with chronic kidney disease stage 5 + 5d and 27 healthy kidney donors were evaluated with hemodynamic measurements before surgery; from these subjects, 11 patients and 11 healthy subjects had vasodilator properties of subcutaneous resistance arteries examined. The measurements were correlated to adipose tissue n-3 polyunsaturated fatty acids. Information on fish intake was obtained from a dietary questionnaire and compared with adipose tissue n-3 polyunsaturated fatty acids.ResultsFish intake and the content of n-3 polyunsaturated fatty acids in adipose tissue did not differ between patients and controls. n-3 polyunsaturated fatty acid levels in adipose tissue were positively correlated to systemic vascular resistance index; (r = 0.44; p = 0.07 and r = 0.62; p < 0.05, chronic kidney disease and healthy subjects respectively) and negatively correlated to cardiac output index (r = −0.69; p < 0.01 and r = −0.50; p < 0.05, chronic kidney disease and healthy subjects respectively). No correlation was observed between n-3 polyunsaturated fatty acid levels in adipose tissue and vasodilator properties in resistance arteries. n-3 PUFA content in adipose tissue increased with increasing self-reported fish intake.ConclusionsThe correlations found, suggest a role for n-3 polyunsaturated fatty acids in hemodynamic properties. However, this is apparently not due to changes in intrinsic properties of the resistance arteries as no correlation was found to n-3 polyunsaturated fatty acids.

show abstract

“…Administration of EPA would be expected to help correct the relative EPA deficiency reported in hemodialysis patients [30,31,32] and increase the EPA/AA ratio that has been inversely associated with adverse CV events and markers of inflammation in this population [35,54]. The potential benefit in reducing CV risk would be expected to be associated with low treatment risk, given the well-characterized safety profile reported in the literature [40,41]; however, this profile needs to be confirmed in hemodialysis patients.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have reported that hemodialysis patients have low plasma levels of EPA and, as a result, lower ratios of EPA to the proinflammatory omega-6 fatty acid arachidonic acid (AA) compared with control populations [30,31,32,33]. In a study of 461 hemodialysis patients, low ratios of EPA/AA and omega-3/omega-6 fatty acids were closely associated with carotid atherosclerosis as measured by ultrasound [34].…”

Section: Eicosapentaenoic Acid As a Potential Therapeutic Approach Tomentioning

confidence: 99%

Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A Review

Borow¹,

Mason

Vijayaraghavan

2017

Cardiorenal Med

View full text Add to dashboard Cite

Background: Patients with end-stage renal disease on hemodialysis have excess cardiovascular disease (CVD) burden with substantially increased CV event rates compared with the general population. Summary: Traditional interventions that, according to standard clinical guidelines, reduce CV risk such as antihypertensive therapy, diet, exercise, and statins are not similarly effective in the hemodialysis population. This raises the question of whether additional risk factors, such as enhanced inflammation and oxidative stress, may drive the increased CVD burden in hemodialysis patients. Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid, is incorporated into the atherosclerotic plaque as well as membrane phospholipid bilayers and produces beneficial effects on inflammatory and oxidative mechanisms involved in atherosclerotic plaque formation and progression. EPA levels and the ratio of EPA to the omega-6 polyunsaturated fatty acid arachidonic acid (AA) are reduced in hemodialysis patients. Serum EPA levels have been inversely correlated with proinflammatory cytokines, and the EPA/AA ratio has been inversely associated with CV events in hemodialysis cohorts. Three recent studies involving over 800 hemodialysis patients and follow-up of 2-3 years suggest that EPA therapy may improve clinical outcomes in this patient population as evidenced by significant reductions in cardiovascular mortality, all-cause mortality, and/or CV events. Key Messages: Further studies with high-purity EPA are warranted in patients on hemodialysis, especially given the fact that other interventions including antihypertensives, diet, exercise, and statins have not provided meaningful benefit.

show abstract

Marine n-3 Polyunsaturated Fatty Acids in Patients With End-stage Renal Failure and in Subjects Without Kidney Disease: A Comparative Study

Cited by 42 publications

References 36 publications

A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease

A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease

Long chain n-3 polyunsaturated fatty acids and vascular function in patients with chronic kidney disease and healthy subjects: a cross-sectional and comparative study

Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A Review

Contact Info

Product

Resources

About